Aura Biosciences Stock Today
| AURA Stock | USD 7.49 0.07 0.94% |
PerformanceVery Weak
| Odds Of DistressLow
|
Aura Biosciences is trading at 7.49 as of the 19th of March 2025, a 0.94 percent increase since the beginning of the trading day. The stock's open price was 7.42. Aura Biosciences has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts. Aura Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 49.95 M outstanding shares of which 1.29 M shares are presently shorted by private and institutional investors with about 7.85 trading days to cover. More on Aura Biosciences
Moving against Aura Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Aura Stock Highlights
Aura Biosciences (AURA) is traded on NASDAQ Exchange in USA. It is located in 80 Guest Street, Boston, MA, United States, 02135 and employs 88 people. Aura Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 370.64 M. Aura Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 49.95 M outstanding shares of which 1.29 M shares are presently shorted by private and institutional investors with about 7.85 trading days to cover.
Aura Biosciences currently holds about 122.13 M in cash with (63.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.17.
Check Aura Biosciences Probability Of Bankruptcy
Ownership AllocationAura Biosciences holds a total of 49.95 Million outstanding shares. The majority of Aura Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aura Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aura Biosciences. Please pay attention to any change in the institutional holdings of Aura Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aura Ownership Details
Aura Biosciences Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Aura Biosciences market risk premium is the additional return an investor will receive from holding Aura Biosciences long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | 0.0951 | |||
| Treynor Ratio | 0.5093 |
Aura Stock Against Markets
Aura Biosciences Corporate Management
| Richard Mountfield | Senior Quality | Profile | |
| Patrick Nealon | Senior Operations | Profile | |
| CPE MBA | Chief RD | Profile | |
| Jill MD | Chief Development | Profile | |
| Amy Elazzouzi | Interim Officer | Profile | |
| Paulo Carvalho | VP Operations | Profile | |
| Bruce MD | Senior Oncology | Profile |
Already Invested in Aura Biosciences?
The danger of trading Aura Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aura Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aura Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aura Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aura Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aura Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aura Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aura Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aura Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aura Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aura Biosciences is measured differently than its book value, which is the value of Aura that is recorded on the company's balance sheet. Investors also form their own opinion of Aura Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aura Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aura Biosciences' market value can be influenced by many factors that don't directly affect Aura Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aura Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aura Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aura Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.